Nuance Investments LLC Has $43.96 Million Stake in Abbott Laboratories (NYSE:ABT)

Paterniano Del Favero
Luglio 20, 2017

Shares of Abbott Laboratories (NYSE:ABT) declined -0.31% to $48.76. Abbott Laboratories accounts for about 3.4% of Nuance Investments LLC's portfolio, making the stock its 10th largest position.

Poplar Forest Capital Llc increased its stake in Abbott Labs (ABT) by 2381.49% based on its latest 2016Q4 regulatory filing with the SEC. But, the company raised its full-year 2017 earnings per share guidance range, which continues to reflect double-digit growth. The institutional investor held 87,025 shares of the water supply company at the end of 2016Q4, valued at $4.87 million, down from 136,699 at the end of the previous reported quarter. ABT has diverse figures for different time frames; starting from week's performance it going forward toward positive percentage of 1.23% in last five regular trading sessions. Banco Santander S.A. bought a new position in shares of Abbott Laboratories during the fourth quarter worth about $5,189,000. It also reduced Xcel Energy Inc (NYSE:XEL) stake by 7,947 shares and now owns 828 shares. Freestone Capital Holdings LLC now owns 25,278 shares of the healthcare product maker's stock valued at $971,000 after buying an additional 17,410 shares during the last quarter. Finally, Marshwinds Advisory Co. raised its stake in shares of Abbott Laboratories by 118.2% in the first quarter. Drexel Morgan & Co. now owns 19,786 shares of the healthcare product maker's stock valued at $760,000 after buying an additional 650 shares during the period.

Now the shares of Abbott Laboratories (ABT) has the trading volume of 4.16 Million shares with the average trading volume of 4330 shares. The stock closing price is now trading upward to its 50 day moving average with change of 4.78%, escalated to its 20 day moving average with figure of 0.32% and above its 200 day moving average with value 13.50%. The company has a market capitalization of $84.58 billion, a P/E ratio of 50.72 and a beta of 1.07.

Abbott Laboratories (NYSE:ABT) stock reached a 1-year peak price of $49.59.

According to the analysts, Abbott Laboratories (NYSE:ABT) is expected to announce $0.61/share EPS for the current quarter.

Abbott Laboratories has a consensus outperform rating from 19 Wall Street analysts, and the number of shares now sold short amount to at least 1.02% of shares outstanding. In the USA, where retail prices can be particularly important to sales, heart rhythm device revenue sank almost 14 percent, according to adjusted figures in Abbott's quarterly earnings presentation Thursday morning.

Last year, it was generating $8 billion in global revenues.

Diluted EPS for trailing twelve months is 0.96 and Quarterly Earnings Growth year over year is 32.6 Percent.

Abbott said it now expects to post adjusted EPS of $2.43 to $2.53, up from its prior forecast for $2.40 to $2.50 this year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, August 15th. Investors of record on Friday, July 14th will be given a dividend of $0.265 per share. The Offer is being made following an Offer to Purchase, dated July 17, 2017 (the "Offer to Purchase"), and in connection with Abbott's formerly declared agreement to acquire Alere (the "Merger").

Worldwide Pediatric Nutrition sales increased 1.4 percent on a reported basis in the second quarter, including an unfavorable 1.1 percent effect of foreign exchange, and increased 2.5 percent on an operational basis. Abbott Laboratories's payout ratio is now 110.42%. The original version of this piece of content can be read at https://stocknewstimes.com/2017/07/19/amg-national-trust-bank-has-2-45-million-stake-in-abbott-laboratories-nyseabt.html.

Several research firms recently weighed in on ABT. Finally, BMO Capital Markets restated a "hold" rating and set a $48.00 price target on shares of Abbott Laboratories in a research report on Tuesday, July 11th. UBS AG reiterated a "neutral" rating and set a $41.00 price target on shares of Abbott Laboratories in a research report on Tuesday, April 18th.

Among 10 analysts covering Parkway Properties (NYSE:PKY), 2 have Buy rating, 0 Sell and 8 Hold. The stock now has a consensus rating of "Buy" and an average target price of $51.33.

In related news, insider Jared Watkin sold 552 shares of the firm's stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $43.82, for a total transaction of $245,392.00.

Tower Research Capital Llc Trc decreased Service Corp Intl (NYSE:SCI) stake by 12,556 shares to 2,286 valued at $65,000 in 2016Q4. Also, insider Stephen R. Fussell sold 196,550 shares of the company's stock in a transaction that occurred on Thursday, June 8th. The stock was sold at an average price of $47.97, for a total value of $26,479.44. Macquarie Group Ltd sold 22,500 shares as the company's stock declined 3.42% while stock markets rallied. The fund owned 989,891 shares of the healthcare product maker's stock after selling 5,410 shares during the period.

Abbott Laboratories ABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market.

Abbott Labs operates through four segments - Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics.

New products lifted pediatric nutrition sales in the United States, but worldwide sales declined due to continuing challenging market conditions in China. It improved, as 83 investors sold ABT shares while 496 reduced holdings.

Altre relazioni OverNewsmagazine

Discuti questo articolo

SEGUI I NOSTRI GIORNALE